Use your antibodies-online credentials, if available.
抗Rat (Rattus) CCL19 抗体:
抗Mouse (Murine) CCL19 抗体:
抗Human CCL19 抗体:
Human Monoclonal CCL19 Primary Antibody for FACS, ICC - ABIN4899709
Berrih-Aknin, Ruhlmann, Bismuth, Cizeron-Clairac, Zelman, Shachar, Dartevelle, de Rosbo, Le Panse: CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia. in Annals of neurology 2009
Show all 4 Pubmed References
Human Monoclonal CCL19 Primary Antibody for FACS, ICC - ABIN4899710
Gibejova, Mrazek, Subrtova, Sekerova, Szotkowska, Kolek, du Bois, Petrek: Expression of macrophage inflammatory protein-3 beta/CCL19 in pulmonary sarcoidosis. in American journal of respiratory and critical care medicine 2003
Show all 4 Pubmed References
Human Polyclonal CCL19 Primary Antibody for IF (p), IHC (p) - ABIN740505
Borrelli, Abrão, Taube, Darb-Esfahani, Köhler, Kaufmann, Chiantera, Mechsner: Immunohistochemical Investigation of Metastasis-Related Chemokines in Deep-Infiltrating Endometriosis and Compromised Pelvic Sentinel Lymph Nodes. in Reproductive sciences (Thousand Oaks, Calif.) 2015
These data show that CCR7 (显示 CCR7 抗体)-CCL19/CCL21 (显示 CCL21 抗体) axis facilitates retention CD4 (显示 CD4 抗体)(+) T lymphocytes at the site of collateral artery remodeling, which is essential for effective arteriogenesis.
the white pulp regions of ME7-infected spleens were smaller, and contained markedly diminished T zones, as compared to control spleens. Although lymphoid tissue inducer cells were not affected, the expression of both CCL19 and CCL21 (显示 CCL21 抗体) was decreased.
a comprehensive model of CCL19 and CCL21 (显示 CCL21 抗体) transport and gradient formation in the lymph nodes (LNs) was built; predicts that ACKR4 in LNs prevents CCL19/CCL21 (显示 CCL21 抗体) accumulation in efferent lymph, but does not control intranodal gradients; instead, it attributes the disrupted interfollicular CCL21 (显示 CCL21 抗体) gradients observed in Ackr4-deficient LNs to ACKR4 loss upstream
The beneficial effects of epicatechin in ameriorating diet-induced obesity and insulin (显示 INS 抗体) resistance could be mediated, at least in part, by marked suppression of CCL19 expression.
Results suggest that baicalin exerts an inhibitory effect on airway inflammation, and this effect may be associated with the inhibition of CCR7 (显示 CCR7 抗体) and its ligands, CCL19 and CCL21 (显示 CCL21 抗体), as well as on the nuclear factor-Kappa B (NF-kappaB (显示 NFKB1 抗体)) pathway in a mouse model of asthma.
Interferon-gamma (IFN-gamma (显示 IFNG 抗体)) and interleukin-12 (IL-12 (显示 IL12A 抗体)) levels in the tumors and plasma were significantly enhanced after processing with recombinant mouse CCL19.
Modulation of the chemokines CCL19 and CCL21 (显示 CCL21 抗体) represents a potent immunoregulatory treatment approach, and thus represents a novel therapeutic target to stabilize atherosclerotic lesions.
CCL19 (ELC) improves TH1 (显示 HAND1 抗体)-polarized immune responses and protective immunity in a murine Her2/neu (显示 ERBB2 抗体) DNA vaccination model.
study shows that CCL19/21 and its possible signaling through CXCR3 (显示 CXCR3 抗体) are required for the development of thymic metallophilic macrophages
Study confirmes that CCL19 induces the invasion and migration of breast cancer cells through the expression of markers of epithelial-mesenchymal transition.
findings connect NOTCH1 (显示 NOTCH1 抗体), DUSP22 (显示 DUSP22 抗体), and CCL19-driven chemotaxis within a single functional network, suggesting that modulation of the homing process may provide a relevant contribution to the unfavorable prognosis associated with NOTCH1 (显示 NOTCH1 抗体) mutations in CLL.
Deletion of this extended C-terminus reduces CCL21 (显示 CCL21 抗体)'s affinity for heparin and transferring the CCL21 (显示 CCL21 抗体) C-terminus to CCL19 enhances heparin binding mainly through non-specific, electrostatic interactions
CCL19 is significantly overexpressed in patients with unstable carotid atherosclerotic plaques and may be a possible novel biomarker for identifying high-risk patients in whom more urgent intervention may be indicated.
CrkL (显示 CRKL 抗体) regulates CCL19 and CCR7 (显示 CCR7 抗体)-induced epithelial-to-mesenchymal transition via ERK (显示 EPHB2 抗体) signaling pathway in epithelial ovarian carcinoma patients.
observed significantly higher concentrations of IL-8 (显示 IL8 抗体) (p < 0.001), MCP-1 (显示 CCL2 抗体) (p = 0.014), and MIP (显示 TNPO1 抗体)-3beta (p = 0.022) in the PF of women with endometriosis than in the controls.
The solution structure of CCL19 is reported. It contains a canonical chemokine (显示 CCL1 抗体) domain. Chemical shift mapping shows the N-termini of PSGL-1 (显示 SELPLG 抗体) and CCR7 (显示 CCR7 抗体) have overlapping binding sites for CCL19 and binding is competitive.
Our findings serve to elucidate the molecular mechanisms underlying the resistin (显示 RETN 抗体) induction of CCL19 expression in ECs and the shear-stress protection against this induction.
The mRNA levels of CCL19/CCL21 (显示 CCL21 抗体) in ankylosing spondylitis hip ligament were significantly higher than in osteoarthritis ligament.
Serum CCL19 and CCL21 (显示 CCL21 抗体) were up-regulated during Rickettsia conorii infection.
This gene is one of several CC cytokine genes clustered on the p-arm of chromosome 9. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene may play a role in normal lymphocyte recirculation and homing. It also plays an important role in trafficking of T cells in thymus, and in T cell and B cell migration to secondary lymphoid organs. It specifically binds to chemokine receptor CCR7.
C-C motif chemokine 19
, chemokine (C-C motif) ligand 19
, CCL19 chemokine
, CC chemokine ligand 19
, small inducible cytokine A19
, chemokine CCL19/MIP-3BETA
, CK beta-11
, EBI1 ligand chemokine
, EBI1-ligand chemokine
, beta chemokine exodus-3
, beta-chemokine exodus-3
, epstein-Barr virus-induced molecule 1 ligand chemokine
, macrophage inflammatory protein 3 beta
, macrophage inflammatory protein 3-beta
, small inducible cytokine subfamily A (Cys-Cys), member 19
, small-inducible cytokine A19
, EBI-1 ligand chemokine
, EBV-induced molecule 1 ligand chemokine
, chemokine CCL19